Dr Bhavesh Poladia, Patritumab Deruxtecan HER3 DXd in EGFR Mutated NSCLC | CRSF

Dr. Bhavesh Poladia presents the findings of the HERTHENA-Lung01 study, evaluating the efficacy of Patritumab Deruxtecan HER3 DXd in EGFR mutated Non-Small Cell Lung Cancer (NSCLC) patients following EGFR TKI and platinum-based chemotherapy. Join us at the CRSF 7th annual year-end review in lung cancer to explore the potential of this targeted therapy in improving outcomes for patients with EGFR mutations. #HERTHENALung01 #NSCLC #EGFRMutations #LungCancerResearch #CRSFReview #MedicalResearch #CancerTreatment Follow us: CRSF Online: https://crsf.in/ Facebook: https://bit.ly/3QfMTrX Twitter: https://bit.ly/3vBQAR7 LinkedIn: https://bit.ly/3zVG7m8 Event Managed By: Horizon Conference Management